Literature DB >> 29214587

Rare Neurodegenerative Diseases: Clinical and Genetic Update.

Antoni Matilla-Dueñas1, Marc Corral-Juan2, Agustí Rodríguez-Palmero Seuma3, Dolores Vilas4, Lourdes Ispierto4, Sara Morais5, Jorge Sequeiros5, Isabel Alonso5, Víctor Volpini6, Carmen Serrano-Munuera7,8, Guillem Pintos-Morell3, Ramiro Álvarez4, Ivelisse Sánchez9.   

Abstract

More than 600 human disorders afflict the nervous system. Of these, neurodegenerative diseases are usually characterised by onset in late adulthood, progressive clinical course, and neuronal loss with regional specificity in the central nervous system. They include Alzheimer's disease and other less frequent dementias, brain cancer, degenerative nerve diseases, encephalitis, epilepsy, genetic brain disorders, head and brain malformations, hydrocephalus, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease), Huntington's disease, and Prion diseases, among others. Neurodegeneration usually affects, but is not limited to, the cerebral cortex, intracranial white matter, basal ganglia, thalamus, hypothalamus, brain stem, and cerebellum. Although the majority of neurodegenerative diseases are sporadic, Mendelian inheritance is well documented. Intriguingly, the clinical presentations and neuropathological findings in inherited neurodegenerative forms are often indistinguishable from those of sporadic cases, suggesting that converging genomic signatures and pathophysiologic mechanisms underlie both hereditary and sporadic neurodegenerative diseases. Unfortunately, effective therapies for these diseases are scarce to non-existent. In this chapter, we highlight the clinical and genetic features associated with the rare inherited forms of neurodegenerative diseases, including ataxias, multiple system atrophy, spastic paraplegias, Parkinson's disease, dementias, motor neuron diseases, and rare metabolic disorders.

Entities:  

Keywords:  Ataxia; Dementia; Genetic diagnosis; Metabolic disorders; Movement disorders; Neuromuscular

Mesh:

Substances:

Year:  2017        PMID: 29214587     DOI: 10.1007/978-3-319-67144-4_25

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

Review 1.  Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders.

Authors:  Mirza Ali Mofazzal Jahromi; Amir Abdoli; Mohammad Rahmanian; Hassan Bardania; Mehrdad Bayandori; Seyed Masoud Moosavi Basri; Alireza Kalbasi; Amir Reza Aref; Mahdi Karimi; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-07-01       Impact factor: 5.590

Review 2.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

3.  NGS-driven molecular diagnosis of heterogeneous hereditary neurological disorders reveals novel and known variants in disease-causing genes.

Authors:  Ayaz Khan; Shixiong Tian; Muhammad Tariq; Sheraz Khan; Muhammad Safeer; Naimat Ullah; Nazia Akbar; Iram Javed; Mahnoor Asif; Ilyas Ahmad; Shahid Ullah; Humayoon Shafique Satti; Raees Khan; Muhammad Naeem; Mahwish Ali; John Rendu; Julien Fauré; Klaus Dieterich; Xenia Latypova; Shahid Mahmood Baig; Naveed Altaf Malik; Feng Zhang; Tahir Naeem Khan; Chunyu Liu
Journal:  Mol Genet Genomics       Date:  2022-08-24       Impact factor: 2.980

4.  Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.

Authors:  John W Rumsey; Case Lorance; Max Jackson; Trevor Sasserath; Christopher W McAleer; Christopher J Long; Arindom Goswami; Melissa A Russo; Shruti M Raja; Karissa L Gable; Doug Emmett; Lisa D Hobson-Webb; Manisha Chopra; James F Howard; Jeffrey T Guptill; Michael J Storek; Miguel Alonso-Alonso; Nazem Atassi; Sandip Panicker; Graham Parry; Timothy Hammond; James J Hickman
Journal:  Adv Ther (Weinh)       Date:  2022-04-05

5.  Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA).

Authors:  Nika Schuermans; Dimitri Hemelsoet; Bart Dermaut; Bruce Poppe; Wim Terryn; Sanne Steyaert; Rudy Van Coster; Paul J Coucke; Wouter Steyaert; Bert Callewaert; Elke Bogaert; Patrick Verloo; Arnaud V Vanlander; Elke Debackere; Jody Ghijsels; Pontus LeBlanc; Hannah Verdin; Leslie Naesens; Filomeen Haerynck; Steven Callens
Journal:  Orphanet J Rare Dis       Date:  2022-05-23       Impact factor: 4.303

Review 6.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

7.  Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer's disease mouse model.

Authors:  Christian Griñán-Ferré; Laura Marsal-García; Aina Bellver-Sanchis; Shukkoor Muhammed Kondengaden; Ravi Chakra Turga; Santiago Vázquez; Mercè Pallàs
Journal:  Aging (Albany NY)       Date:  2019-12-04       Impact factor: 5.682

Review 8.  Biomarkers in Rare Demyelinating Disease of the Central Nervous System.

Authors:  Marina Boziki; Styliani-Aggeliki Sintila; Panagiotis Ioannidis; Nikolaos Grigoriadis
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

9.  Nanobiotechnology: A New Frontier for Brain Disorders.

Authors:  Pasquale Picone
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

Review 10.  Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.

Authors:  Bibhuti Bhusan Kakoti; Rajashri Bezbaruah; Nasima Ahmed
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.